{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:23:00Z","timestamp":1782915780964,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,13]]},"DOI":"10.7759\/cureus.48719","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T11:07:38Z","timestamp":1699873658000},"source":"Crossref","is-referenced-by-count":6,"title":["Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential"],"prefix":"10.7759","author":[{"given":"Priyanshu","family":"Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyambabu","family":"Rauniyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyesh","family":"Sapkale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Hallucinogens. (2023). Accessed. August 15, 2023: https:\/\/my.clevelandclinic.org\/health\/articles\/6734-hallucinogens-lsd-peyote-psilocybin-and-pcp.."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present &  future","volume":"142","author":"Rucker JJ","year":"2018","unstructured":"Rucker JJ, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present &  future. Neuropharmacology. 2018, 142:200-18. 10.1016\/j.neuropharm.2017.12.040","journal-title":"Neuropharmacology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2019.21.2\/dnutt","article-title":"Psychedelic drugs-a new era in\u2028psychiatry?","volume":"21","author":"Nutt D","year":"2019","unstructured":"Nutt D. Psychedelic drugs-a new era in\u2028psychiatry?. Dialogues Clin Neurosci. 2019, 21:139-47. 10.31887\/DCNS.2019.21.2\/dnutt","journal-title":"Dialogues Clin Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris RL","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017, 42:2105-13. 10.1038\/npp.2017.84","journal-title":"Neuropsychopharmacology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.17.1110","article-title":"Psychedelic drugs in the treatment of anxiety, depression and addiction","volume":"138","author":"Kvam TM","year":"2018","unstructured":"Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskr Nor Laegeforen. 2018, 138:10.4045\/tidsskr.17.1110","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2017.00240","article-title":"The \"Endless Trip\" among the NPS Users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review","volume":"8","author":"Orsolini L","year":"2017","unstructured":"Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The \"Endless Trip\" among the NPS Users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry. 2017, 8:240. 10.3389\/fpsyt.2017.00240","journal-title":"Front Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt DJ","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010, 376:1558-65. 10.1016\/S0140-6736(10)61462-6","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"Krebs TS","year":"2013","unstructured":"Krebs TS, Johansen P\u00d8. Psychedelics and mental health: a population study. PLoS One. 2013, 8:e63972. 10.1371\/journal.pone.0063972","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus E","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011, 25:1434-52. 10.1177\/0269881110382466","journal-title":"J Psychopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks PS","year":"2015","unstructured":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015, 29:280-8. 10.1177\/0269881114565653","journal-title":"J Psychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al.. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016, 30:1181-97. 10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols DE","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016, 68:264-355. 10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"ref13","unstructured":"Psychedelic drug. (2023). Accessed. August 15, 2023: https:\/\/www.britannica.com\/science\/psychedelic-drug."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2016_466","article-title":"Effect of hallucinogens on unconditioned behavior","volume":"36","author":"Halberstadt AL","year":"2018","unstructured":"Halberstadt AL, Geyer MA. Effect of hallucinogens on unconditioned behavior. Curr Top Behav Neurosci. 2018, 36:159-99. 10.1007\/7854_2016_466","journal-title":"Curr Top Behav Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan AC","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022, 25:1407-19. 10.1038\/s41593-022-01177-4","journal-title":"Nat Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.024","article-title":"Structure of a hallucinogen-activated Gq-Coupled 5-HT(2A) serotonin receptor","volume":"182","author":"Kim K","year":"2020","unstructured":"Kim K, Che T, Panova O, et al.. Structure of a hallucinogen-activated Gq-Coupled 5-HT(2A) serotonin receptor. Cell. 2020, 182:1574-1588.e19. 10.1016\/j.cell.2020.08.024","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti ME","year":"2017","unstructured":"Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017, 42:2114-27. 10.1038\/npp.2017.86","journal-title":"Neuropsychopharmacology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06083-y","article-title":"Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review","volume":"239","author":"Sarparast A","year":"2022","unstructured":"Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology (Berl). 2022, 239:1945-76. 10.1007\/s00213-022-06083-y","journal-title":"Psychopharmacology (Berl)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: a review","volume":"24","author":"Garcia-Romeu A","year":"2016","unstructured":"Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: a review. Exp Clin Psychopharmacol. 2016, 24:229-68. 10.1037\/pha0000084","journal-title":"Exp Clin Psychopharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-assisted group therapy: a systematic review","volume":"51","author":"Trope A","year":"2019","unstructured":"Trope A, Anderson BT, Hooker AR, Glick G, Stauffer C, Woolley JD. Psychedelic-assisted group therapy: a systematic review. J Psychoactive Drugs. 2019, 51:174-88. 10.1080\/02791072.2019.1593559","journal-title":"J Psychoactive Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15544","article-title":"Psychedelic-inspired approaches for treating neurodegenerative disorders","volume":"162","author":"Saeger HN","year":"2022","unstructured":"Saeger HN, Olson DE. Psychedelic-inspired approaches for treating neurodegenerative disorders. J Neurochem. 2022, 162:109-27. 10.1111\/jnc.15544","journal-title":"J Neurochem"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11013-022-09814-0","article-title":"Hallucinations and hallucinogens: psychopathology or wisdom?","volume":"47","author":"Bouso JC","year":"2023","unstructured":"Bouso JC, Ona G, Kohek M, Dos Santos RG, Hallak JE, Alc\u00e1zar-C\u00f3rcoles M\u00c1, Obiols-Llandrich J. Hallucinations and hallucinogens: psychopathology or wisdom?. Cult Med Psychiatry. 2023, 47:576-604. 10.1007\/s11013-022-09814-0","journal-title":"Cult Med Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking psychedelics seriously","volume":"21","author":"Byock I","year":"2018","unstructured":"Byock I. Taking psychedelics seriously. J Palliat Med. 2018, 21:417-21. 10.1089\/jpm.2017.0684","journal-title":"J Palliat Med"},{"key":"ref24","unstructured":"Hallucinogen | Definition, Types, & Effects . (2023). Accessed. 15 August 2023: https:\/\/www.britannica.com\/science\/hallucinogen.."},{"key":"ref25","unstructured":"Hallucinogen. (2023). Accessed. August 15, 2023: https:\/\/www.camh.ca\/en\/health-info\/mental-illness-and-addiction-index\/hallucinogens.."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.07.018","article-title":"The behavioral pharmacology of hallucinogens","volume":"75","author":"Fantegrossi WE","year":"2008","unstructured":"Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol. 2008, 75:17-33. 10.1016\/j.bcp.2007.07.018","journal-title":"Biochem Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211069100","article-title":"Adverse effects of psychedelics: from anecdotes and misinformation to systematic science","volume":"36","author":"Schlag AK","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022, 36:258-72. 10.1177\/02698811211069100","journal-title":"J Psychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01361-x","article-title":"Sustained effects of single doses of classical psychedelics in humans","volume":"48","author":"Knudsen GM","year":"2023","unstructured":"Knudsen GM. Sustained effects of single doses of classical psychedelics in humans. Neuropsychopharmacology. 2023, 48:145-50. 10.1038\/s41386-022-01361-x","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173129","article-title":"Use and abuse of dissociative and psychedelic drugs in adolescence","volume":"203","author":"Bates ML","year":"2021","unstructured":"Bates ML, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacol Biochem Behav. 2021, 203:173129. 10.1016\/j.pbb.2021.173129","journal-title":"Pharmacol Biochem Behav"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082520","article-title":"Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders","volume":"27","author":"Lowe H","year":"2022","unstructured":"Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W. Psychedelics: alternative and potential therapeutic options for treating mood and anxiety disorders. Molecules. 2022, 27:10.3390\/molecules27082520","journal-title":"Molecules"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/182886-psychedelic-drugs-or-hallucinogens-exploring-their-medicinal-potential","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:36Z","timestamp":1707509376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/182886-psychedelic-drugs-or-hallucinogens-exploring-their-medicinal-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.48719","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,13]]}}}